Platinum-refractory Ovarian Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-03-18
Clinical Trial Update: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) [Phase 3]
Phase 3 clinical trial evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and Bevacizumab versus physician's choice of ch…